Category - Developments

Developments

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

March 19, 2020

Developments

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) treated the first patient in its Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The trial, being conducted at Stanford...

March 19, 2020

Developments

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

Alpine Immune Sciences (NASDAQ:ALPN) received two FDA orphan drug designations for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (GvHD). ALPN-101 is a selective dual T-cell co-stimulation...

March 19, 2020

Developments

Sigilon Therapeutics in $80.3-million series B financing

Closely-held Sigilon Therapeutics completed an $80.3-million Series B financing to advance its Shielded Living Therapeutics platform to the clinic. The funding will support the first-in-human clinical trial of Sigilon’s...

March 18, 2020

Developments

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...

March 12, 2020

Developments

Bee Vectoring kick starts U.S. west coast expansion

Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) closed three new grower deals with berry producers in Oregon and Washington states to use the company’s proprietary bee delivery system, VECTORITE...

March 11, 2020

Developments

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Albireo Pharma (NASDAQ:ALBO) completed patient enrollment in its Phase 2 trial of elobixibat for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The trial enrolled 47...

March 10, 2020

Developments

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

According to the FDA, the passage of the 2018 Farm Bill has led to the misperception that all products made from or containing hemp, including those made with cannabidiol (CBD), were now legal to sell in interstate...

March 10, 2020

Developments

Imagin Medical gets additional positive physician feedback on i/Blue Imaging System

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) has continued to collect additional input on its i/Blue Imaging System from physicians in the United States and Canada. Leading urologists...

March 10, 2020

Developments

Kala Pharma reports positive results from Phase 3 dry eye disease trial

Kala Pharmaceuticals’ (NASDAQ:KALA) EYSUVIS met both primary efficacy endpoints in a Phase 3 trial for the short-term treatment of dry eye disease. The trial, called STRIDE 3, demonstrated a statistically significant...

March 9, 2020

Category - Developments

Subscribe